Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis

被引:4
作者
Nelli, Fabrizio [1 ]
Virtuoso, Antonella [1 ]
Giannarelli, Diana [2 ]
Fabbri, Agnese [3 ]
Berrios, Julio Rodrigo Giron [3 ]
Marrucci, Eleonora [3 ]
Fiore, Cristina [3 ]
Ruggeri, Enzo Maria [3 ]
机构
[1] Cent Hosp Belcolle, Dept Oncol & Hematol, Thorac Oncol Unit, I-01100 Viterbo, Italy
[2] Fdn Policlin Univ A Gemelli, Ist Ricovero & Cura Carattere Sci IRCCS, Biostat Unit, Sci Directorate, I-00168 Rome, Italy
[3] Cent Hosp Belcolle, Dept Oncol & Hematol, Med Oncol Unit, I-01100 Viterbo, Italy
关键词
non-small-cell lung cancer; immune checkpoint inhibitors; first-line therapy; second-line therapy; acetaminophen; disease control benefit; survival; NONSMALL; ASSOCIATION; RESPONSES; SURVIVAL; EFFICACY; CRITERIA; RECIST;
D O I
10.3390/curroncol30090589
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
(1) Background: Several studies have investigated potential interactions between immune checkpoint inhibitors (ICIs) and commonly prescribed medications. Although acetaminophen (APAP) has not been considered susceptible to interaction with ICIs, recent research has shown that detectable plasma levels of this drug can hinder the efficacy of PD-1/PD-L1 blockade therapies. A reliable assessment of the potential interaction between APAP and ICIs in advanced non-small cell lung cancer (NSCLC) patients would be worthwhile since it is often prescribed in this condition. We sought to evaluate the impact of the concomitant use of APAP in patients with advanced NSCLC on PD-1/PD-L1 blockade using real-world evidence. (2) Methods: This study included consecutive patients with histologically proven stage IV NSCLC who underwent first-line therapy with pembrolizumab as a single agent or in combination with platinum-based chemotherapy, or second-line therapy with pembrolizumab, nivolumab, or atezolizumab. The intensity of APAP exposure was classified as low (therapeutic intake lasting less than 24 h or a cumulative intake lower than 60 doses of 1000 mg) or high (therapeutic intake lasting more than 24 h or a total intake exceeding 60 doses of 1000 mg). The favorable outcome of anti-PD-1/PD-L1 therapies was defined by durable clinical benefit (DCB). Progression-free survival (PFS) and overall survival (OS) were relevant to our efficacy analysis. Propensity score matching (PSM) methods were applied to adjust for differences between the APAP exposure subgroups. (3) Results: Over the course of April 2018 to October 2022, 80 patients were treated with first-line pembrolizumab either as single-agent therapy or in combination with platinum-based chemotherapy. During the period from June 2015 to November 2022, 145 patients were given anti-PD-1/PD-L1 blockade therapy as second-line treatment. Subsequent efficacy analyses relied on adjusted PSM populations in both treatment settings. Multivariate testing revealed that only the level of APAP and corticosteroid intake had an independent effect on DCB in both treatment lines. Multivariate Cox regression analysis confirmed high exposure to APAP and immunosuppressive corticosteroid therapy as independent predictors of shorter PFS and OS in both treatment settings. (4) Conclusions: Our findings would strengthen the available evidence that concomitant intake of APAP blunts the efficacy of ICIs in patients with advanced NSCLC. The detrimental effects appear to depend on the cumulative dose and duration of exposure to APAP. The inherent shortcomings of the current research warrant confirmation in larger independent series.
引用
收藏
页码:8117 / 8133
页数:17
相关论文
共 50 条
[31]   Pretreatment lung immune prognostic index as biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab [J].
Veccia, Antonello ;
Sforza, Vincenzo ;
Vattemi, Emanuela ;
Inno, Alessandro ;
Kinspergher, Stefania ;
Dipasquale, Mariachiara ;
Gori, Stefania ;
Morabito, Alessandro ;
Baldi, Ileana ;
Caffo, Orazio .
IMMUNOTHERAPY, 2021, 13 (13) :1093-1103
[32]   The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases [J].
Rui Kitadai ;
Yusuke Okuma ;
Taiki Hakozaki ;
Yukio Hosomi .
Journal of Cancer Research and Clinical Oncology, 2020, 146 :777-785
[33]   Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study [J].
Benguerfi, Soraya ;
Lesimple, Thierry ;
Houot, Roch ;
Ricordel, Charles ;
Legoupil, Delphine ;
Alleaume, Corinne ;
Lamy, Regine ;
Lagadec, Delphine Deniel ;
Corre, Romain .
ACTA ONCOLOGICA, 2022, 61 (11) :1339-1346
[34]   Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study [J].
Nasu, Izumi ;
Kondo, Masahiro ;
Uozumi, Ryuji ;
Takada, Shinya ;
Nawata, Shuichi ;
Iihara, Hirotoshi ;
Okumura, Yohei ;
Takemoto, Masashi ;
Mino, Kozo ;
Sasaki, Tadanori ;
Hirose, Chiemi ;
Aomori, Tohru ;
Shimano, Rena ;
Maeno, Ken ;
Oizumi, Satoshi ;
Kusumoto, Sojiro ;
Ohno, Yasushi ;
Ikemura, Shinnosuke ;
Takai, Daiya ;
Hara, Azusa ;
Kawazoe, Hitoshi ;
Nakamura, Tomonori .
JOURNAL OF CANCER, 2023, 14 (05) :676-688
[35]   Favourable outcomes in patients with early-stage non-small-cell lung cancer operated on by video-assisted thoracoscopic surgery: a propensity score-matched analysis [J].
Dziedzic, Robert ;
Marjanski, Tomasz ;
Binczyk, Franciszek ;
Polanska, Joanna ;
Sawicka, Wioletta ;
Rzyman, Witold .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2018, 54 (03) :547-553
[36]   Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors [J].
Abbar, B. ;
Castelbajac, V. De ;
Gougis, P. ;
Assoun, S. ;
Pluvy, J. ;
Tesmoingt, C. ;
Theou-Anton, N. ;
Cazes, A. ;
Namour, C. ;
Khalil, A. ;
Gounant, V. ;
Besse, B. ;
Zalcman, G. ;
Brosseau, S. .
LUNG CANCER, 2021, 152 :109-118
[37]   Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer [J].
Derosa, L. ;
Hellmann, M. D. ;
Spaziano, M. ;
Halpenny, D. ;
Fidelle, M. ;
Rizvi, H. ;
Long, N. ;
Plodkowski, A. J. ;
Arbour, K. C. ;
Chaft, J. E. ;
Rouche, J. A. ;
Zitvogel, L. ;
Zalcman, G. ;
Albiges, L. ;
Escudier, B. ;
Routy, B. .
ANNALS OF ONCOLOGY, 2018, 29 (06) :1437-1444
[38]   Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer [J].
Decatris, Marios P. ;
O'Byrne, Kenneth J. .
FUTURE ONCOLOGY, 2016, 12 (15) :1805-1822
[39]   Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer [J].
Reinhorn, Daniel ;
Jacobi, Oded ;
Icht, Oded ;
Dudnik, Elizabeth ;
Rotem, Ofer ;
Zer, Alona ;
Goldstein, Daniel A. .
IMMUNOTHERAPY, 2020, 12 (04) :235-243
[40]   Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer [J].
Giri, Anshu ;
Walia, Simrit S. ;
Gajra, Ajeet .
REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) :297-305